Literature DB >> 33569344

Risk and Prognosis of Secondary Bladder Cancer After Radiation Therapy for Rectal Cancer: A Large Population-Based Cohort Study.

Xu Guan1, Ran Wei1, Runkun Yang1,2, Zhao Lu1, Enrui Liu1, Zhixun Zhao1, Haipeng Chen1, Ming Yang1, Zheng Liu1, Zheng Jiang1, Xishan Wang1,2.   

Abstract

BACKGROUND: Although radiation therapy (RT) improves local control for rectal cancer (RC), the long-term risks from RT, including development of a secondary malignancy, are controversial. The risk and prognosis of secondary bladder cancer (SBC) in RC patients undergoing RT have not been adequately studied. Our goal is to investigate the impact of RT on the risk of developing SBC and assess their survival outcomes.
METHODS: This large population-based study included RC patients as their initial primary cancer from nine registries of the Surveillance, Epidemiology and End Results (SEER) database between 1973 and 2015. The cumulative incidence of SBC was assessed by using Fine and Gray's competing risk regression. The standardized incidence ratio (SIR) was used to compare the incidence of SBC in RC survivors to the US general population. The Kaplan-Meier method was used to evaluate the 10-year overall survival (OS) and 10-year cancer specific survival (CSS) for patients with SBC.
RESULTS: Of 74,646 RC patients, 24,522 patients were treated with surgery and RT and 50,124 patients were treated with surgery alone. The incidence of SBC was 1.85% among patients who received RT and 1.24% among patients who did not. The incidence of SBC in RC patients who received RT was higher than the US general population (SIR, 1.35; 95% CI, 1.19-1.53, P<0.05), and decreased with increasing age at diagnosis, and increased with time since diagnosis. In competing risk regression analysis, undergoing RT was associated with a higher risk of SBC (hazard ratio [HR], 1.443, 95% confidence interval [CI], 1.209-1.720; P<0.001). The results of the dynamic SIR for SBC revealed that a slightly increased risk of SBC was observed after RT in the early latency, and was significantly related to the variations of age at RC diagnosis and decreased with time progress. The 10-year OS and CSS among SBC patients after RT were comparable to SBC patients after NRT.
CONCLUSION: Radiation was associated with an increased risk of developing SBC in RC patients, and special attention should be paid to the surveillance of these patients.
Copyright © 2021 Guan, Wei, Yang, Lu, Liu, Zhao, Chen, Yang, Liu, Jiang and Wang.

Entities:  

Keywords:  cancer specific survival; overall survival; prognostic factor; radiation therapy; rectal cancer; secondary bladder cancer

Year:  2021        PMID: 33569344      PMCID: PMC7868538          DOI: 10.3389/fonc.2020.586401

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  16 in total

1.  Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery.

Authors:  D J Brenner; R E Curtis; E J Hall; E Ron
Journal:  Cancer       Date:  2000-01-15       Impact factor: 6.860

2.  Occurrence of second cancers in patients treated with radiotherapy for rectal cancer.

Authors:  Helgi Birgisson; Lars Påhlman; Ulf Gunnarsson; Bengt Glimelius
Journal:  J Clin Oncol       Date:  2005-09-01       Impact factor: 44.544

3.  Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients--a Dutch colorectal cancer group study.

Authors:  K C M J Peeters; C J H van de Velde; J W H Leer; H Martijn; J M C Junggeburt; E Klein Kranenbarg; W H Steup; T Wiggers; H J Rutten; C A M Marijnen
Journal:  J Clin Oncol       Date:  2005-09-01       Impact factor: 44.544

4.  Incidence of second tumors after treatment with or without radiation for rectal cancer.

Authors:  A J M Rombouts; N Hugen; M A G Elferink; T Feuth; P M P Poortmans; I D Nagtegaal; J H W de Wilt
Journal:  Ann Oncol       Date:  2017-03-01       Impact factor: 32.976

5.  A population-based analysis of second primary cancers after irradiation for rectal cancer.

Authors:  Wayne S Kendal; Garth Nicholas
Journal:  Am J Clin Oncol       Date:  2007-08       Impact factor: 2.339

Review 6.  Radiation-induced second cancers: the impact of 3D-CRT and IMRT.

Authors:  Eric J Hall; Cheng-Shie Wuu
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-05-01       Impact factor: 7.038

7.  Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008.

Authors:  Nicholas Donin; Christopher Filson; Alexandra Drakaki; Hung-Jui Tan; Alex Castillo; Lorna Kwan; Mark Litwin; Karim Chamie
Journal:  Cancer       Date:  2016-07-05       Impact factor: 6.860

8.  Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial.

Authors:  David Sebag-Montefiore; Richard J Stephens; Robert Steele; John Monson; Robert Grieve; Subhash Khanna; Phil Quirke; Jean Couture; Catherine de Metz; Arthur Sun Myint; Eric Bessell; Gareth Griffiths; Lindsay C Thompson; Mahesh Parmar
Journal:  Lancet       Date:  2009-03-07       Impact factor: 79.321

Review 9.  Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis.

Authors:  Christopher J D Wallis; Alyson L Mahar; Richard Choo; Sender Herschorn; Ronald T Kodama; Prakesh S Shah; Cyril Danjoux; Steven A Narod; Robert K Nam
Journal:  BMJ       Date:  2016-03-02

10.  Second primary malignancy risk after radiotherapy in rectal cancer survivors.

Authors:  Ti-Hao Wang; Chia-Jen Liu; Tze-Fan Chao; Tzeng-Ji Chen; Yu-Wen Hu
Journal:  World J Gastroenterol       Date:  2018-10-28       Impact factor: 5.742

View more
  3 in total

1.  Incident Cardiovascular Disease Among Adults With Cancer: A Population-Based Cohort Study.

Authors:  D Ian Paterson; Natasha Wiebe; Winson Y Cheung; John R Mackey; Edith Pituskin; Anthony Reiman; Marcello Tonelli
Journal:  JACC CardioOncol       Date:  2022-03-15

2.  Neoadjuvant Chemotherapy plus Bevacizumab Combined with Total Mesorectal Excision in Treating Locally Advanced Rectal Cancer Patients with BRAF Mutation: Clinical Benefit and Safety.

Authors:  Jintian Song; Yi Wang; Hui Yu; Liang Zheng; Xiongchao Cai; Yigui Chen
Journal:  Comput Math Methods Med       Date:  2021-12-09       Impact factor: 2.238

3.  Risk and prognosis of secondary bladder cancer after radiation therapy for pelvic cancer.

Authors:  Shuofeng Li; Ran Wei; Guanhua Yu; Hengchang Liu; Tianli Chen; Xu Guan; Xishan Wang; Zheng Jiang
Journal:  Front Oncol       Date:  2022-08-24       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.